BI
BVF Inc Portfolio holdings
AUM
$2.8B
This Quarter Return
+21.94%
1 Year Return
+17.96%
3 Year Return
+404.14%
5 Year Return
+563.41%
10 Year Return
+5,885.83%
AUM
$2.74B
AUM Growth
+$2.74B
(+15%)
Cap. Flow
+$297M
Cap. Flow
% of AUM
10.84%
Top 10 Holdings %
Top 10 Hldgs %
49.25%
Holding
82
New
4
Increased
18
Reduced
6
Closed
10
Top Buys
| 1 |
Protagonist Therapeutics
PTGX
|
$86.8M |
| 2 |
Galapagos
GLPG
|
$79.8M |
| 3 |
Ionis Pharmaceuticals
IONS
|
$51.4M |
| 4 |
Structure Therapeutics
GPCR
|
$41.6M |
| 5 |
Revolution Medicines
RVMD
|
$36.8M |
Top Sells
| 1 |
Arcus Biosciences
RCUS
|
$47.6M |
| 2 |
Cullinan Oncology
CGEM
|
$44.1M |
| 3 |
Viridian Therapeutics
VRDN
|
$27.2M |
| 4 |
CNCE
Concert Pharmaceuticals, Inc.
CNCE
|
$21.2M |
| 5 |
Annexon
ANNX
|
$19.5M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
MoonLake Immunotherapeutics
MLTX
$3.54B
| $465M | 17.01% | 21,751,284 | – | – |
|
2
Kymera Therapeutics
KYMR
$2.95B
| $140M | 5.13% | 4,739,004 +46,400 | +1% | +$1.37M |
|
3
Axsome Therapeutics
AXSM
$6.05B
| $131M | 4.81% | 2,131,100 +376,100 | +21% | +$23.2M |
|
|
4
Revolution Medicines
RVMD
$7.1B
| $107M | 3.92% | 4,955,588 +1,700,000 | +52% | +$36.8M |
|
|
5
Ionis Pharmaceuticals
IONS
$6.79B
| $91.5M | 3.35% | 2,560,761 +1,438,952 | +128% | +$51.4M |
|
|
6
Protagonist Therapeutics
PTGX
$3.67B
| $86.8M | 3.17% | +3,775,900 | New | +$86.8M |
|
|
7
Galapagos
GLPG
$2.07B
| $83.7M | 3.06% | 2,165,109 +2,065,109 | +2,065% | +$79.8M |
|
8
Kura Oncology
KURA
$686M
| $82.3M | 3.01% | 6,730,983 +2,930,000 | +77% | +$35.8M |
|
9
Repare Therapeutics
RPTX
$71.7M
| $81.6M | 2.98% | 8,291,988 | – | – |
|
|
PNT
10
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
| $76.8M | 2.81% | 10,563,748 +1,386,000 | +15% | +$10.1M |
|
11
Xoma
XOMA
$392M
| $76.7M | 2.8% | 3,633,743 +22,249 | +0.6% | +$470K |
|
12
GH Research
GHRS
$837M
| $74.1M | 2.71% | 9,275,158 | – | – |
|
13
4D Molecular Therapeutics
FDMT
$288M
| $68.9M | 2.52% | 4,007,413 | – | – |
|
14
Xenon Pharmaceuticals
XENE
$2.98B
| $65.4M | 2.39% | 1,827,958 +556,715 | +44% | +$19.9M |
|
15
Merus
MRUS
$4.98B
| $54.8M | 2% | 2,978,420 | – | – |
|
16
Zymeworks
ZYME
$1.12B
| $53.1M | 1.94% | 5,870,000 | – | – |
|
17
Tyra Biosciences
TYRA
$675M
| $52.1M | 1.9% | 3,239,595 +767,268 | +31% | +$12.3M |
|
18
Relay Therapeutics
RLAY
$619M
| $51.4M | 1.88% | 3,120,521 -755,500 | -19% | -$12.4M |
|
19
Syndax Pharmaceuticals
SNDX
$1.41B
| $45.3M | 1.65% | 2,143,197 +692,000 | +48% | +$14.6M |
|
20
Crinetics Pharmaceuticals
CRNX
$2.92B
| $44M | 1.61% | 2,736,613 | – | – |
|
|
21
Structure Therapeutics
GPCR
$1.11B
| $41.6M | 1.52% | +1,750,000 | New | +$41.6M |
|
22
Immunovant
IMVT
$2.56B
| $39.7M | 1.45% | 2,561,000 | – | – |
|
23
Lexicon Pharmaceuticals
LXRX
$400M
| $39.2M | 1.43% | 16,149,179 | – | – |
|
24
Replimune Group
REPL
$422M
| $37.8M | 1.38% | 2,143,036 +620,407 | +41% | +$11M |
|
|
CTIC
25
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
| $37M | 1.35% | 8,813,021 | – | – |
|